News
Google News
20+ hour, 29+ min ago (21+ words) Beijing Tong Ren Tang Chinese Medicine (03613. HK)'s Chinese Patent Medicine "Jinchai Shihu San" Approved for Sale in Macau'AASTOCKS. com...
SINO BIOPHARMACEUTICAL (01177. HK)'s Vetricotobat Monoclonal Antibody for Gastric Cancer Completes First Patient Enrollment in Phase III Clinical Trial
6+ day, 1+ hour ago (102+ words) AASTOCKS. com SINO BIOPHARMACEUTICAL (01177. HK)+0. 340 (+5. 832%) Short selling $160. 17 M; Ratio 22. 565% announced that Vetricotobat Monoclonal Antibody (CLDN18. 2 ADC), a Class 1 innovative drug independently developed by Lixin Pharmaceutical, a wholly-owned subsidiary of the Group, is undergoing a Phase III pivotal clinical trial (LM302-03-201) in combination…...
Hong Kong Federation of Insurers Reviewing Optimization of Voluntary Health Insurance Products
6+ day, 9+ hour ago (64+ words) AASTOCKS. com Zi-lan Li, a member of the Life Insurance Council of the Hong Kong Federation of Insurers, stated that the industry believes medical inflation has remained elevated in recent years, and that it is now an appropriate time to…...
LAEKNA (02105. HK) Phase III Breast Cancer Trial Meets Primary Endpoint with Significant PFS Improvement
6+ day, 10+ hour ago (84+ words) AASTOCKS. com LAEKNA-B (02105. HK)+0. 260 (+1. 529%) Short selling $1. 07 M; Ratio 1. 989% announced that LAE002 (afuresertib) in combination with fulvestrant has achieved strong and positive topline results in the Phase III clinical trial "AFFIRM-205". The study targeted patients with HR+/HER2- locally advanced or metastatic breast…...
Fosun Pharma (02196. HK) Subsidiary's New Breast Cancer Neoadjuvant Therapy Approved for Clinical Trial
1+ week, 5+ day ago (123+ words) Fosun Pharma (02196. HK) announced that its subsidiary, Shanghai Henlius Biotech and its holding subsidiary Henlius, have received approval from the National Medical Products Admini. .. Open a new. .. Fosun Pharma (02196. HK)0. 000 (0. 000%) Short selling $2. 72 M; Ratio 7. 325% announced that its subsidiary, Shanghai Henlius…...
Beijing Tianxing Medical Passes Listing Hearing
1+ week, 6+ day ago (35+ words) AASTOCKS. com Beijing Tianxing Medical has passed the listing hearing and plans to list on the Main Board in Hong Kong, with CITIC Securities and CCBI acting as joint sponsors....
Zai Lab (09688. HK) Enters Global Collaboration with Amgen (AMGN. US) to Explore Novel ADC and Bi TE Combination Therapy
2+ week, 5+ day ago (20+ words) AASTOCKS. com...
State Tobacco Monopoly Administration Proposes Revisions to Certain E-cigarette Regulatory Policy Documents
2+ week, 5+ day ago (111+ words) AASTOCKS. com The State Tobacco Monopoly Administration issued a notice on proposed revisions to certain e-cigarette regulatory policy documents (consultation draft), stating that the e-cigarette industry has been incorporated into regulation in accordance with the law, with a scientifically sound…...
BIOCYTOGEN (02315. HK) Partner NEOK Bio's Bispecific ADC NEOK002 Approved for US Clinical Trial
3+ week, 4+ day ago (72+ words) AASTOCKS. com BIOCYTOGEN-B (02315. HK)+4. 650 (+8. 643%) Short selling $3. 56 M; Ratio 2. 145% announced that its partner, NEOK Bio, Inc. , has recently received approval from the United States Food and Drug Administration for the investigational new drug clinical trial application of NEOK002. NEOK002 is an antibody-drug conjugate…...
CN NHSA: Long-term Care Insurance Boosts RMB60 B+ in Social Capital Investment Since 2016 Pilot
3+ week, 5+ day ago (79+ words) AASTOCKS. com The establishment of the long-term care insurance system has given rise to new business formats and models, such as the development, production, and leasing of assistive devices, assessment work of disability level, and participation of social forces in…...